Searchable abstracts of presentations at key conferences in endocrinology

ea0049ep1420 | Thyroid (non-cancer) | ECE2017

Prognostic value of preoperative serum calcitonin concentration on primary surgery outcomes in medullary thyroid cancer

Gawlik Tomasz , Kukulska Aleksandra , Wygoda Zbigniew , Krajewska Jolanta , Stobiecka Ewa , Czarniecka Agnieszka , Jarzab Barbara

Calcitonin assessment in thyroid diseases is recommended when medullary thyroid cancer (MTC) is suspected in fine needle biopsy, as well as in ‘suspicious for a follicular neoplasm’ class, especially oxyphilic type, in patients with germinal RET proto-oncogene mutation and in nondiagnostic biopsy when no surgical treatment is planned. This assessment is also suggested before any planned thyroid surgery to exclude MTC. Beyond diagnosis confirmation it is also suggeste...

ea0049ep1440 | Thyroid (non-cancer) | ECE2017

Management of treatment-related toxicity caused by multi kinase inhibitors administered due to advanced thyroid carcinoma

Krajewska Jolanta , Kukulska Aleksandra , Handkiewicz-Junak Daria , Paliczka-Cieslik Ewa , Olczyk Tomasz , Gawlik Tomasz , Ledwon Aleksandra , Michalik Barbara , Jarzab Barbara

Multi kinase inhibitors (MKIs) constitute a new therapeutic option in advanced RAI-refractory differentiated thyroid cancer (DTC) and medullary thyroid carcinoma (MTC). To date four different MKIs demonstrated a beneficial effect on progression free survival in DTC (sorafenib, lenvatinib) and MTC (vandetanib and cabozantinib). However, the treatment related toxicity, which potentially may limit their clinical use and lead to a negative impact on the quality of life, have been ...

ea0056gp226 | Thyroid Cancer - Diagnostics & Treatments | ECE2018

Significant acceleration in dynamics of medullary thyroid cancer markers concentration – report of 26 cases

Gawlik Tomasz , Krajewska Jolanta , Kukulska Aleksandra , Wygoda Zbigniew , Szpak-Ulczok Sylwia , Krol Aleksandra , Puch Zbigniew , Jarzab Barbara

Calcitonin and carcinoembryonal antigen are biochemical markers of medullary thyroid carcinoma (MTC). Assessment of the dynamics of their serum concentration allow for calculation of their doubling times that are independent risk factors for overall survival and progression-free survival in MTC. It is generally accepted that the dynamics and the doubling times remain stable during follow-up.Aim: The aim of the study was to retrospectively verify the stab...

ea0037ep904 | Thyroid cancer | ECE2015

Adjuvant radioiodine (RAI) treatment reduces the risk of relapse in low advanced differentiated thyroid carcinoma (DTC)

Krajewska Jolanta , Jarzab Michal , Czarniecka Agnieszka , Kukulska Aleksandra , Handkiewicz-Junak Daria , Wygoda Zbigniew , Puch Zbigniew , Paliczka-Cieslik Ewa , Roskosz Jozef , Jarzab Barbara

The routine use of adjuvant RAI treatment in low-risk DTC remains controversial due to the lack of unequivocal evidences of its effectiveness in radically operated subjects. The aim of the study was a retrospective evaluation of long-term outcomes of combined DTC treatment to evaluate the impact of adjuvant RAI therapy in the low risk group. Primary hypothesis was: ‘if adjuvant RAI treatment was unnecessary, a delay in RAI administration would have no impact on long-term ...

ea0037ep909 | Thyroid cancer | ECE2015

The risk of thyroid cancer (TC) in a thyroid nodule on the basis of a tertiary reference TC center experience

Blewaska Aleksandra , Sygula Aleksandra , Chmielik Ewa , Stobiecka Ewa , Zembala-Nozynska Ewa , Czarniecka Agnieszka , Sacher Aleksander , Krajewska Jolanta , Kukulska Aleksandra , Jarzab Barbara

A global TC risk in a single thyroid nodule is rather small and ranges between 1 and 11%. However, taking into consideration Bethesda System for Reporting Thyroid Cytopathology TC risk varies between distinct categories: 0–3, 5–15, 15–30, 60–75 and 97–99% for Bethesda class II–VI, respectively. However, these values may differ in a centre, specialized in TC. Therefore, the aim of this study was to evaluate the TC risk in patients referred to a ter...

ea0035p1098 | Thyroid Cancer | ECE2014

Risk factors of cancer relapse in differentiated thyroid carcinomas

Krajewska Jolanta , Jarzab Michal , Czarniecka Agnieszka , Roskosz Jozef , Kukulska Aleksandra , Handkiewicz-Junak Daria , Puch Zbigniew , Paliczka-Cieslik Ewa , Wygoda Zbigniew , Jarzab Barbara

Introduction: Reliable prognostic factors are crucial to choose the optimal treatment strategy and follow-up for differentiated thyroid carcinomas (DTC) patients. Thus, the aim of the study was a retrospective evaluation of prognostic factors of cancer relapse in patients treated in a single institution.Material: The study group consisted of 510 DTC patients, staged pT1b-T4N0-N1M0, treated with total thyroidectomy followed by complementary 131...

ea0070aep923 | Thyroid | ECE2020

Adverse effects of tyrosine kinase inhibitors in advanced thyroid carcinoma – a summary of 10-year experience

Krajewska Jolanta , Kukulska Aleksandra , Paliczka-Cieslik Ewa , Gawlik Tomasz , Olczyk Tomasz , Ledwon Aleksandra , Michalik Barbara , Kropinska Aleksadra , Handkiewicz-Junak Daria , Jarzab Barbara

Introduction: To date, only four tyrosine kinase inhibitors (TKIs) have demonstrated beneficial effect on progression free survival in advanced medullary thyroid cancer (MTC; vandetanib and cabozantinib) andradioiodine-refractory differentiated thyroid cancer (RR-DTC; sorafenib and lenvatinib). However, there is still lack of unequivocal proofs of their significant impact on overall survival. Therefore, treatment-related side effects and their potential impact on quality of li...

ea0040p6 | (1) | ESEBEC2016

Toxicity of tyrosine kinase inhibitors in the treatment of thyroid cancer – a 10-year experience resume

Krajewska Jolanta , Kukulska Aleksandra , Paliczka-Cieślik Ewa , Handkiewicz-Junak Daria , Gawlik Tomasz , Olczyk Tomasz , Kropińska Aleksandra , Michalik Barbara , Gubała Elżbieta , Jarząb Barbara

Targeted therapy based on tyrosine kinase inhibitors (TKIs) constitutes a new treatment modality in thyroid cancer (TC). Their efficacy in prolongation of progression free survival in comparison to placebo has been documented in phase III studies. However, a problem of their tolerability has recently risen as numerous side effects influencing the quality of life may potentially limit their clinical use. Therefore, we decided to carry out a retrospective analysis of the frequen...

ea0035oc5.5 | Adrenal & Thyroid | ECE2014

Validation of follicular thyroid cancer molecular classifier in fine-needle aspiration biopsy samples

Pfeifer Aleksandra , Bartosz Wojtas , Malgorzata Oczko-Wojciechowska , Aleksandra Kukulska , Agnieszka Czarniecka , Markus Eszlinger , Thomas Musholt , Tomasz Stokowy , Ewa Stobiecka , Jolanta Krajewska , Dagmara Rusinek , Tomasz Tyszkiewicz , Monika Kowal , Michal Jarzab , Steffen Hauptmann , Dariusz Lange , Ralf Paschke , Barbara Jarzab

Introduction: Follicular adenomas (FTA) and carcinomas (FTC) are thyroid tumours that are indistinguishable in the fine needle aspiration biopsy (FNAB). In our previous research we concentrated on post-operative material and developed the classifier, which discriminates the FTC and FTA, based on formalin-fixed paraffin-embedded (FFPE) material. The classifier was based on expression of five genes and gave the promising sensitivity of 71% and specificity of 72%. The aim of the ...